Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.

Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, Russell RJ, van der Werf S, Thomson RJ, Naffakh N, von Itzstein M.

Nat Commun. 2010 Nov 16;1:113.

2.

Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.

Rudrawar S, Kerry PS, Rameix-Welti MA, Maggioni A, Dyason JC, Rose FJ, van der Werf S, Thomson RJ, Naffakh N, Russell RJ, von Itzstein M.

Org Biomol Chem. 2012 Nov 21;10(43):8628-39. doi: 10.1039/c2ob25627d.

PMID:
22976385
3.

Complexity in influenza virus targeted drug design: interaction with human sialidases.

Chavas LM, Kato R, Suzuki N, von Itzstein M, Mann MC, Thomson RJ, Dyason JC, McKimm-Breschkin J, Fusi P, Tringali C, Venerando B, Tettamanti G, Monti E, Wakatsuki S.

J Med Chem. 2010 Apr 8;53(7):2998-3002. doi: 10.1021/jm100078r.

PMID:
20222714
4.

Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.

Rudrawar S, Dyason JC, Maggioni A, Thomson RJ, von Itzstein M.

Bioorg Med Chem. 2013 Aug 15;21(16):4820-30. doi: 10.1016/j.bmc.2013.05.054. Epub 2013 Jun 6.

PMID:
23800724
5.

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.

Taylor NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J.

J Med Chem. 1998 Mar 12;41(6):798-807.

PMID:
9526556
6.

Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.

Zhang Q, Yang J, Liang K, Feng L, Li S, Wan J, Xu X, Yang G, Liu D, Yang S.

J Chem Inf Model. 2008 Sep;48(9):1802-12. doi: 10.1021/ci800041k. Epub 2008 Aug 16.

PMID:
18707092
7.

Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition.

Chavas LM, Tringali C, Fusi P, Venerando B, Tettamanti G, Kato R, Monti E, Wakatsuki S.

J Biol Chem. 2005 Jan 7;280(1):469-75. Epub 2004 Oct 22.

8.

Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.

Singh S, Jedrzejas MJ, Air GM, Luo M, Laver WG, Brouillette WJ.

J Med Chem. 1995 Aug 18;38(17):3217-25.

PMID:
7650674
10.

Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.

Atigadda VR, Brouillette WJ, Duarte F, Ali SM, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck EA, Finley J, Luo M, Air GM, Laver GW.

J Med Chem. 1999 Jul 1;42(13):2332-43.

PMID:
10395473
11.

Structural studies on the Pseudomonas aeruginosa sialidase-like enzyme PA2794 suggest substrate and mechanistic variations.

Xu G, Ryan C, Kiefel MJ, Wilson JC, Taylor GL.

J Mol Biol. 2009 Feb 27;386(3):828-40. doi: 10.1016/j.jmb.2008.12.084. Epub 2009 Jan 10.

PMID:
19166860
12.

A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.

Barrère B, Driguez PA, Maudrin J, Doutheau A, Aymard M, Quash G.

Arch Virol. 1997;142(7):1365-80.

PMID:
9267449
13.
15.

A sialidase mutant displaying trans-sialidase activity.

Paris G, Ratier L, Amaya MF, Nguyen T, Alzari PM, Frasch AC.

J Mol Biol. 2005 Jan 28;345(4):923-34.

PMID:
15588836
16.

Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.

Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M.

J Mol Biol. 1999 Nov 12;293(5):1107-19.

PMID:
10547289
18.

Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice.

Hughes MT, Matrosovich M, Rodgers ME, McGregor M, Kawaoka Y.

J Virol. 2000 Jun;74(11):5206-12.

19.

On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).

Mitrasinovic PM.

Biophys Chem. 2009 Mar;140(1-3):35-8. doi: 10.1016/j.bpc.2008.11.004. Epub 2008 Nov 20.

PMID:
19117662
20.

Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM, Walsh GM.

Antimicrob Agents Chemother. 1998 Apr;42(4):801-7.

Items per page

Supplemental Content

Write to the Help Desk